Auragenix N.V. Eyes Lucrative Generic Drugs Market in Europe; Company in Talks with Poland Based Biopharmcor Sp. z o.o.

Share Article

Auragenix N.V.will soon be extending its portfolio management activities into Europe`s multi billion Euro healthcare industry.

Auragenix N.V. (http://www.auragenix.com) announced today that its Management Board has launched a new two pronged investment portfolio strategy for the Netherlands based investment management firm. While the Company intends to continue its investment activity in niche segments of the commercial real estate market in Central Europe, it will soon be extending its portfolio management activities into Europe`s multi-billion Euro healthcare industry.

The Company reported that it is currently negotiating with BioPharmcor Sp. z o.o. (http://www.biopharmcor.pl) to acquire a 100% stake in the Warsaw Poland based start-up generic drugs firm and anticipates a closing by early May. BioPharmcor intends to launch a pipeline of generic medicines over the next 24 months that will target, in particular, the male gender population of the healthcare marketplace.

A spokesperson for Auragenix N.V. explained that , "In assessing an investment in the generic drugs sector of the pharmaceutical industry, the Board took into account the opportunity for building substantial revenues and profitability over the short to medium term with a relatively modest investment. In BioPharmcor we see a solid business case for enhancing shareholder values while balancing our portfolio with strategic positions in the burgeoning commercial real estate sector in Central Europe.”

The signing of a definitive Purchase Agreement with BioPharmcor Sp. z o.o. is subject to completion of satisfactory due diligence and final approval by the Management Boards of both companies.

The generic drugs market currently represents the fastest growing segment of the European pharmaceutical industry. The generics market in Europe had total revenues of Euro 29 billion in 2010, representing a compound annual growth rate (CAGR) of 7.4% between 2006 and 2010. Through 2015, the market is expected to trend upward at a CAGR of 5.2% with annual sales topping Euro 37.4 billion over the next 3 years.

Auragenix N.V. is a publicly held investment management firm headquartered in Amsterdam, The Netherlands. In 2010, the company entered the commercial real estate market in Central Europe through its acquisition of Warsaw based Auragen Real Estate Sp. z o.o.

Shares of Auragenix N.V. are listed on the Open Market segment of the Frankfurt Borse (Symbol : AUIN). A public offering of Auragenix shares was not made in connection with their inclusion on the Open Market Frankfurt.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

MICHAEL WEXLER
auragenix nv
1(613) 292-2307
Email >
Visit website